Salvage surgery following downstaging of advanced non‐small cell lung cancer by targeted therapy

Kuo Li,Xiaonian Cao,Bo Ai,Han Xiao,Quanfu Huang,Zheng Zhang,Qian Chu,Li Zhang,Xiaofang Dai,Yongde Liao

DOI: https://doi.org/10.1111/1759-7714.14044

IF: 3.223

2021-06-15

Thoracic Cancer

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Advanced non-small cell lung cancer (NSCLC) accounts for a high proportion of lung cancer cases. Targeted therapy improve the survival in these patients, but acquired drug resistance will inevitably occur. If tumor downstaging is achieved after targeted therapy, could surgical resection before drug resistance improve clinical benefits for patients with advanced NSCLC? Here, we conducted a clinical trial showing that for patients with advanced driver gene mutant NSCLC who did not progress after targeted therapy, salvage surgery (SS) could improve progression-free survival (PFS). Herein, we retrospectively reviewed our former clinical trial and thoracic cancer database in our medical institutions.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We identified patients with advanced driver gene mutant NSCLC treated with targeted therapy plus SS or targeted therapy alone in our former clinical trial and our thoracic cancer database from July 2016 to July 2019. PFS was compared between the targeted therapy plus SS group and the targeted therapy only group using the log-rank test.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>We identified 73 patients with driver gene mutant NSCLC who were treated with targeted therapy and 18 treated with targeted therapy plus SS.Among the 18 patients treated with targeted therapy plus SS, there were no obvious perioperative complications and deaths. Targeted therapy followed by SS resulted in a significantly longer PFS compared with targeted therapy alone (23.4 months VS 12.9 months, <i>p</i> = 0.0004). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Salvage surgery after tumor downstaging is a promising therapeutic strategy for some patients with advanced (stage IIIB–IV) NSCLC and may offer a new therapeutic option for multidisciplinary comprehensive treatment of lung cancer.</p></section>

oncology,respiratory system

What problem does this paper attempt to address?

This paper mainly discusses the possibility and effectiveness of salvage surgery (SS) for advanced non-small cell lung cancer (NSCLC) after targeted therapy. The study pointed out that although targeted therapy can improve the survival of these patients, drug resistance is inevitable. If the tumor can be reduced (downstaging) through targeted therapy before the development of resistance, can surgical resection bring greater clinical benefits? Through a retrospective review of data from July 2016 to July 2019, the study found that compared with 73 patients who only received targeted therapy, the SS group of 18 patients who underwent SS after targeted therapy had a significantly prolonged progression-free survival (PFS) (23.4 months vs. 12.9 months). These results suggest that salvage surgery after tumor reduction might be a promising treatment strategy for some advanced NSCLC patients, providing a new option for multidisciplinary comprehensive treatment of lung cancer. However, this study has certain limitations, including retrospective design and small sample size, and more prospective randomized studies are needed to validate the effectiveness of this strategy.